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BACKGROUND: Potentiation of anticancer activity of capecitabine is required to improve its therapeutic index. In colorectal cancer
(CRC) cells, we evaluated whether the histone deacetylase-inhibitor vorinostat may induce synergistic antitumour effects in
combination with capecitabine by modulating the expression of thymidine phosphorylase (TP), a key enzyme in the conversion of
capecitabine to 5-florouracil (5-FU), and thymidylate synthase (TS), the target of 5-FU.
METHODS: Expression of TP and TS was measured by real-time PCR, western blotting and immunohistochemistry. Knockdown of TP
was performed by specific small interfering RNA. Antitumour activity of vorinostat was assessed in vitro in combination with the
capecitabine active metabolite deoxy-5-fluorouridine (50-DFUR) according to the Chou and Talay method and by evaluating
apoptosis as well as in xenografts-bearing nude mice in combination with capecitabine.
RESULTS: Vorinostat induced both in vitro and in vivo upregulation of TP as well as downregulation of TS in cancer cells, but not in
ex vivo treated peripheral blood lymphocytes. Combined treatment with vorinostat and 50-DFUR resulted in a synergistic
antiproliferative effect and increased apoptotic cell death in vitro. This latter effect was impaired in cells where TP was knocked. In vivo,
vorinostat plus capecitabine potently inhibited tumour growth, increased apoptosis and prolonged survival compared with control or
single-agent treatments.
CONCLUSIONS: Overall, this study suggests that the combination of vorinostat and capecitabine is an innovative antitumour strategy and
warrants further clinical evaluation for the treatment of CRC.
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Although higher response rates have been achieved using the
latest poly-chemotherapy regimens with fluoropyrimidines
(5-florouracil (5-FU) and capecitabine) representing the backbone
of therapies including agents such as oxaliplatin or irinotecan
and/or new molecular targeted drugs such as cetuximab or
bevacizumab, colorectal cancer (CRC) remains the second leading
cause of cancer death in the Western countries. Resistance to
chemotherapy and multi-step carcinogenesis that limits the
efficacy of targeted compounds are probably the leading causes
of the limited activity of anticancer strategies in CRC.
Histone deacetylase inhibitors (HDAC-Is) represent a new class
of anticancer agents that modulate the expression of cell cycle
regulation, survival and differentiation genes by enhancing histone
acetylation, thus affecting multiple pathways in tumour cells with
minimal effects on normal tissues (Budillon et al, 2005, 2007;
Marks, 2007; Lane and Chabner, 2009). Several HDAC-Is exhibited
antitumour effects in preclinical models (Budillon et al, 2007), and
some of them are in advanced clinical development either as single
agents or in combination with conventional chemotherapeutics or
targeted agents (Budillon et al, 2007; Lane and Chabner, 2009).
Histone deacetylase inhibitors act very selectively to alter the
transcription of 2–5% of expressed genes (Budillon et al, 2007) by
mechanisms that cannot be solely attributed to the level of histone
acetylation (Johnstone and Licht, 2003). Acetylation of other
proteins such as p53, a-tubulin and heat shock protein 90, have
also been described (Johnstone and Licht, 2003). Among the most
promising HDAC-Is, vorinostat (suberoylanilide hydroxamic acid)
has shown significant preclinical and clinical antitumour activity
in both haematological malignancies and solid tumours and
represents the first HDAC-I to be approved by the Food and Drug
Administration for the treatment of cutaneous T-cell lymphoma in
patients with progressive, persistent or recurrent disease during or
following two systemic therapies (Marks, 2007).
Several studies have shown that the expression of the enzyme
thymidylate synthase (TS) can be regulated by HDAC-Is (Glaser
et al, 2003; Lee et al, 2006; Tumber et al, 2007; Di Gennaro et al,
2009; Fazzone et al, 2009). Thymidylate synthase is an essential
enzyme for the de novo synthesis of thymidilate (dTMP) and
subsequently DNA synthesis and is a critical target for
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s5-FU Ackland et al, 2002). High levels of TS expression have
been correlated with poorer overall patient survival in
several tumours and resistance to 5-FU (Ackland et al, 2002).
We have recently demonstrated that vorinostat induces synergistic
antitumour activity in CRC cell lines in combination with either
5-FU or raltitrexed, a selective quinazoline antifolate TS inhibitor,
and sensitises 5-FU-resistant CRC cells to 5-FU. We have also
shown that down-modulation of TS protein induced by vorinostat
within 24h represented a key factor in enhancing the effects of
both drugs in sensitive and resistant tumour cells (Di Gennaro
et al, 2009).
Although the antineoplastic activity of 5-FU could be improved
by continuous infusion or biochemical modulation with
leucovorin, the inconvenience and morbidity associated
with long-term central venous catheters suggested the need of
alternative regimens. Capecitabine is an orally administered inactive
prodrug that is converted into 5-FU by a three-step process in situ.
The key step, the conversion of deoxy-5-fluorouridine (50-DFUR)
into active 5-FU is catalysed by thymidine phosphorylase (TP),
which is expressed at elevated levels by the liver and many tumours,
allowing capecitabine to be specifically targeted to the site of the
cancer, leading to relatively high local concentrations of 5-FU in
tumour cells (Bollag and Hartmann, 1980; Walko and Lindley,
2005). Cytotoxicity of 5-FU mainly results from incorporation of the
drug into replicating RNA after the conversion to FUTP and
thymidine depletion following TS inhibition induced by FdUMP.
Thymidine phosphorylase can convert 5-FU to FdUrd by adding
deoxyribose-1-P donors, which are readily phosphorylated by
thymidine kinase to FdUMP (de Bruin et al, 2003). Consequently,
TP represents the rate-limiting enzyme in the activation of
50-DFUR and capecitabine, suggesting that increasing TP expression
might enhance sensitivity of tumour cells to these prodrugs. In this
regard, preclinical and clinical studies showed that overexpression
of TP by direct transfection of human TP cDNA into cancer cells
or its induction by cytokines, chemotherapeutics such as cyclo-
phosphamide and taxanes or by irradiation resulted in increased
sensitivity to 50-DFUR or capecitabine (Haraguchi et al, 1993;
Patterson et al, 1995; Kato et al, 1997; de Bruin et al, 2003; Toi et al,
2005). Conversely, suppression of TP expression by specific small
interfering RNA (siRNA) in cancer cells and low or deficient
intratumoural TP activity impaired 5-FU therapeutic efficacy
in preclinical studies and in cancer patients, respectively (Salonga
et al, 2000; de Bruin et al, 2003; Thanasai et al, 2010). These data
provided additional evidence supporting the importance of TP in
fluoropyrimidine sensitivity.
Clinical trials with single-agent capecitabine showed improved
tolerability and comparable efficacy to intravenous 5-FU/leucovorin
therapy in patients with metastatic CRC, leading to approval of
capecitabine for use as first-line therapy in this disease (Walko and
Lindley, 2005; Schmoll and Arnold, 2006; Cassidy et al, 2008).
These considerations have compelled us to study whether
vorinostat and capecitabine used in combination could have
synergistic antitumour effects. In the present study, we provided
evidence that by downregulating TS and upregulating TP mRNA
and protein expression, vorinostat demonstrated synergistic
antitumour effects both in vitro and in vivo in combination with
50-DFUR and capecitabine, respectively.
MATERIALS AND METHODS
Materials
Vorinostat was provided by Merck and Co., Inc. (Rahway, NJ,
USA). Stock solutions were prepared in DMSO and diluted to
appropriate concentrations in culture medium before addition to
the cells. MS-275, trichostatin A (TSA), valproic acid (VPA) were
obtained from Alexis Biochemicals (San Diego, CA, USA), LBH589
was provided by Novartis Pharmaceuticals (East Hanover, NJ,
USA), tubacin and niltubacin were provided by Dr SL Schreiber
and Dr Ralph Mazitschek (Haggarty et al, 2003). 5-Fluorouracil
(5-FU) was supplied by Teva Pharmaceutical Industries Ltd.
(Netanya, Israel), folinic acid (FA) was obtained from Wyeth
Pharma GmbH (Mu ¨nster, Germany) and 50-deoxy-5-fluorouridine
(50-DFUR) and capecitabine (Xeloda) were provided by
F Hoffmann-La Roche Ltd. (Basel, Switzerland). All media, serum,
antibiotics and glutamine were from Cambrex Bio Science
(Verviers, Belgium).
Cell culture and cell proliferation assay
LoVo, SW620, HT29 and LS174T cell lines were all from American
Type Culture Collections (Rockville, MD, USA); 5-FU-resistant
HT29 cell lines (HT29FU) have been described before (Di Gennaro
et al, 2009). The LoVo cell line was grown in RPMI 1640 medium,
whereas HT29, HT29FU, SW620 and LS174T were grown in
Dulbecco’s modified Eagle’s medium. Both media were supple-
mented with 10% heat-inactivated foetal bovine serum, 50Uml
 1
of penicillin, 500mgml
 1 of streptomycin, and 4mmoll
 1 of
glutamine in a humidified atmosphere of 95% air and 5% CO2
at 371C.
Cell survival/proliferation was measured in quadruplicate in
96-well plates by a spectrophotometric dye incorporation assay
using sulforhodamine B (ICN Biomedicals, Irvine, CA, USA) after
96h from treatment, as described before (Di Gennaro et al, 2009).
Carboxylesterase activity is required as the first metabolic step
in the activation of capecitabine, but this enzyme has low-level
expression in most cancer cell lines. Thus, all in vitro studies
in cancer cells were performed with capecitabine-metabolite
50-DFUR, which requires the presence of TP to be converted into
the active 5-FU drug. Because FA was tested at 10mM and did not
exhibit any effect on cell proliferation when given alone, 5-FU/FA
was considered a single drug. Peripheral blood lymphocytes
(PBLs) were obtained from a healthy donor by gradient separation
with Lymphocyte separation medium (BioWhittaker, Walkersville,
MD, USA) and grown for 24h in RPMI. Floating lymphocytes
were collected and treated with the indicated concentration of
vorinostat.
In vitro drugs combination studies
Drug combination studies were based on concentration-effect
curves generated as a plot of the fraction of unaffected (surviving)
cells vs drug concentration (Chou and Talalay, 1984; Chou et al,
1994). Serial dilutions of equipotent doses of the two agents in
combination (vorinostat and 50-DFUR) were tested. Synergism,
additivity or antagonism was quantified by determining the
combination index (CI) calculated by the Chou–Talalay equation,
as described elsewhere (Magne et al, 2002; Bruzzese et al, 2006,
2009; Avallone et al, 2007; Di Gennaro et al, 2009). A CI o0.9,
CI¼0.9–1.2 and CI: 41.2 indicated synergistic, additive or
antagonistic effect, respectively (Magne et al, 2002; Di Gennaro
et al, 2009). Dose reduction index (DRI) represents the measure of
how much the dose of each drug in a synergistic combination may
be reduced at a given effect level compared with the doses of each
drug alone (Chou and Talalay, 1984).
Protein extraction and western blotting
Cells grown and treated as indicated were collected, lysed and
separated on SDS polyacrilamide gel electrophoresis, as described
elsewhere (Bruzzese et al, 2006; Di Gennaro et al, 2009). After
electrophoresis, proteins were transferred to nitrocellulose paper,
immunoblotted with specific antibodies (Abs) and probed with
the appropriate horseradish peroxidase-linked IgG. Immuno-
reactive bands were detected by enhanced chemiluminescence
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s(GE Healthcare, Milan, Italy). The following primary Abs were
used: thymidylate synthase (TS)-Ab from Rockand Immuno-
chemicals, Inc. (Gilbertsville, PA, USA), acetyl-H3-Ab from upstate
(Lake Placid, NY, USA), poly-(ADP-ribose)-polymerase (PARP)-
Ab from BD Biosciences (San Jose, CA, USA), g-tubulin-Ab from
Santa Cruz Biotechnology (Santa Cruz, CA, USA), platelet-derived
endothelial growth factor (TP)-Ab from Acris Antibodies GmbH
(Herford, Germany) and GAPDH-Ab, cleaved caspase 3-Ab and
BAX-Ab from Cell Signalling Technology (Boston, MA, USA).
Densitrometric analysis of western blotting data was performed by
NIH Image J software (National Institutes of Health, Bethesda, MD,
USA).
Flow cytometry analysis of apoptosis
Analysis of apoptosis was performed on LoVo cells treated with
vorinostat and/or 50-DFUR, at the indicated concentrations, after
72h of treatment. Briefly, adherent and floating cells were
harvested, fixed in 70% ethanol and stored at  201C until
analysis. After nuclear DNA staining with propidium iodide, flow
cytometry was done by a FACScan flow cytometer (Becton
Dickinson, San Jose, CA, USA). Apoptosis was determined by
evaluating the percentage of cells with DNA content o2N, PI
fluorescence was collected as FL3 (Log scale) by the CellFIT
software (Becton Dickinson, San Jose, CA, USA) and the data were
acquired after analysis of at least 20000 events.
Reverse transcription-PCR (RT–PCR) and real-time PCR
RNA was isolated using the Trizol reagent as indicated by the
manufacturer’s instructions (Invitrogen, Carlsbad, CA, USA). The
RT–PCR assay was performed using the High capacity cDNA
reverse transcription kit (Applied Biosystems, Foster City, CA,
USA).
TS (Hs00926280_m1), TP (TYMP, Hs00157317_m1) and
GADD45 (Hs99999173_m1) mRNA expressions were quantified
using the ABI Prism 7900 HT Sequence Detection System (Applied
Biosystems, Foster City, CA, USA) utilising the 50-nuclease method
with a two-step PCR protocol (951C for 10min, followed by 40
cycles for 15s and 601C for 1min). Each gene was tested in each
cell line in three replicates, and three independent experiments
were performed. To quantify the relative changes in gene
expression, the  2
DDCT method (Livak and Schmittgen, 2001)
was used, and reactions were normalised to endogenous b-actin
gene expression levels (Human ACTB, Applied Biosystems, Foster
City, CA, USA).
Transient knockdown of TP using siRNA
siRNA sequences against human TP were designed and synthesised
by Stealth RNAi, oligo ID HSS141896 (Invitrogen). A stealth RNAi
Negative control Duplexes (Invitrogen) was used as a control for
non-sequence-specific effects.
Thymidine phosphorylase siRNA or control siRNA (33nM) was
transiently transfected into SW620 cells using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions. Briefly,
siRNA:Lipofectamine mixure complexes were incubated for
20min at room temperature and then added to cells growing in
100-mm petri dish. After 24h the complexes were replaced by
complete medium and cells were treated as indicated and assayed
as reported.
In vivo xenograft assay
Female BALB/c athymic (nuþ/nuþ) mice that were 5–6 weeks of
age and weighed 21–23g were purchased from Charles River
Laboratories (Milan, Italy). The research protocol was approved,
and mice were housed and maintained under specific pathogen-free
conditions in the Animal Care Facility of the G Pascale
National Cancer Institute in accordance with the institutional
guidelines of the Italian Ministry of Health Animal Care and Use
Committee. Mice, housed five per cage, were supplied with food
and water ad libitum, maintained under aseptic conditions in a
ventilated rack system and were acclimatised for 1 week before
being injected with cancer cells. SW620 cells (5 10
6) in 200ml PBS
were injected subcutaneously in the right flank area of the mice.
When established tumours were palpable, mice were randomised
into four experimental groups (n¼9). Based on pilot studies (data
not shown) and previous reports (Butler et al, 2000; Fujimoto-
Ouchi et al, 2001; Blanquicett et al, 2005), mice were treated p.o.
with vorinostat (100mgkg
 1 melted in DMSO and diluted in PEG)
and/or capecitabine (359mgkg
 1 in 40mM citrate buffer (pH 6)
containing 5% gum arabic) 5 days/week. Each drug was given in a
volume of 100ml, and mice were treated with vorinostat in the
morning and with capecitabine in the afternoon. Mice in the
control group were treated with both PEG and citrate buffer/Arabic
gum vehicles. Tumour size was measured with a caliper two to
three times per week by the modified ellipsoid formula
(p/6) AB
2, where A is the longest and B is the shortest
perpendicular axis of an assumed ellipsoid corresponding to
tumour mass (Bruzzese et al, 2006). Body weight was measured
three times per week to control for treatment toxicity. Mice were
killed by cervical dislocation when evidence of advanced bulky
disease was present (established cutoff about 2000mm
3). The day
of killing was considered the day of death for survival evaluation.
Survival analysis was computed by the Kaplan–Meier method.
Tumour growth delay (TGD) was determined as %TGD¼
((T C)/C) 100, where T and C are the mean times in days
required to reach the same fixed tumour volume in the treated
group and control group, respectively (Bruzzese et al, 2006).
In vivo drug combination studies were evaluated by CalcuSyn
(Biosoft, Cambridge, UK). For the calculation of CI, the values of
cell kill for a fixed tumour volume were considered (determined by
the log cell kill (LCK)). Log cell kill was determined as
LCK¼(T C)/(3.3 Td), where Td represents the mean control
group doubling time required to reach a fixed tumour volume,
expressed in days, whereas T and C are the same values as
described above (Bruzzese et al, 2006).
Histology and immunohistochemistry (IHC)
SW620 xenografts were collected, fixed in 10% buffered formalin
and paraffin-embedded. Five sections from each tissue were
stained, one with hematoxylin and eosin stain (H&E), one for
terminal deoxynucleotidyl transferase (TdT)-mediated dNTP-
labelling (TUNEL) assay and three for IHC. Sections 4mm-thick
were deparaffinised and rehydrated, and the antigen retrieval
technique was performed in pH 6.0 buffer in a microwave for
3min. Hematoxylin and eosin staining was performed using
standard histological technique. For IHC, the sections were
incubated with the following primary Abs: monoclonal mouse
thymidylate synthase-Ab (TS106, Dako, Glostrup, Denmark),
monoclonal mouse platelet-derived endothelial growth factor
(TP)-Ab (Vision biosystems Novocastra, Newcastle, UK) or
monoclonal rabbit acetil-H3-(Lys9/Lys14)-Ab (Cell Signaling
Technology, Boston, MA, USA). The sections were then processed
with a peroxidase detection system reagent kit (Novocastra,
Newcastle, UK). Apoptosis was evaluated by the TUNEL method
using the Fragel DNA fragmentation detection kit colorimetric-
TdT enzyme by Calbiochem–Merck KgaA (Darmstadt, Germany).
Necrotic areas were evaluated as a percentage comparing the total
tumour volume to the volume of inner tumoural necrosis and were
evaluated for all tumours. The mitotic index was expressed as
number of mitotic figures in 10 high-magnification fields. Tumour
sections stained for TUNEL, TS, TP or acetil-H3 were scored based
on percentage of positive cells. Study slides were examined by a
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ssingle pathologist (RF), who was blinded to the final pathology
interpretation. Images were captured using a light microscope with
a2 0  or 40  objective using standard bright-field illumination.
The group means were calculated at n¼5–7 tumours per group.
All data are presented as the average±s.d.
Statistics
The results of in vitro cell proliferation are expressed as the means
for at least three independent experiments done in quadruplicates,
and the s.d. is indicated.
The results of apoptosis by flow cytometry analysis and real-
time PCR were expressed as the means for at least three
independent experiments (±s.d.), and the statistical significance
of differences was determined by two-sided Student’s t-test.
Representative results from western blotting and IHC from a
single experiment are presented; additional experiments yielded
similar results. Statistical analysis of in vivo mouse survival was
carried out by the w
2-test. Statistical significance of differences in
tumour growth and in IHC results were determined by the one-way
ANOVA and Holm–Sidak methods, and a P-value of o0.05 was
used to indicate statistical significance. All statistical evaluations
were done using Sigma Stat software (Systat Software Inc.,
San Jose, California, USA).
RESULTS
Antiproliferative effects of vorinostat and
fluoropyrimidines in CRC cell lines
All examined CRC cell lines were equally sensitive to the
antiproliferative effect of vorinostat. Two out of five cell lines
(HT29, LoVo) were sensitive to all fluoropyrimidines tested (5-FU,
5-FU modulated by FA, 50-DFUR). SW620 cells were resistant to
the capecitabine metabolite 50-DFUR, whereas two cell lines,
LS174T and HT29-FU (a subline selected by continuous exposure
of sensitive HT29 cells to step wise increasing concentration of
5-FU; Di Gennaro et al, 2009), appeared resistant to all
fluoropyrimidines (Table 1).
Apparently, KRAS and p53 status or the basal expression of
TS protein, the enzyme target of 5-FU, did not correlate with
the sensitivity to fluoropyrimidines and vorinostat. However,
undetectable expression of TP protein, the critical enzyme in
conversion of 50-DFUR to the active compound 5-FU, correlates
with resistance to 50-DFUR in three out of four cell lines (Table 1
and Figure 1A).
Vorinostat and other HDAC-Is modulate TS and TP
expression in CRC cell lines
As previously reported by us and other groups, vorinostat induced
a marked reduction of TS protein level within 24h of treatment in
LoVo, LS174T and SW620 cell lines. Surprisingly, we observed that
TP protein expression was induced by vorinostat in all cell lines
after 24 and 48h, and this effect was dose-dependent and was
clearly induced also by low-dose (0.25mM) vorinostat (Figure 1B).
Even in LoVo cells, where the upregulation of TP was less evident,
densitometric analysis demonstrated a two-fold increase of the
protein expression in cells treated with 0.25mM of vorinostat, and
about a four-fold increase in cells treated with 2mM of vorinostat.
Furthermore, as shown in Figure 1B and C, vorinostat-induced
downregulation of TS, as well as upregulation of TP protein levels,
correlates with attenuation and increase of TS and TP mRNA
transcript levels, respectively. Specifically, we observed a clear
downregulation of TS transcript in LS174T cells after 6h with a
four-fold reduction after 24h, paralleled by an upregulation of TP
transcript that was also evident after 6h with a 27-fold induction at
24h. Similar effects were observed in SW620 cells, with a peak of
four-fold reduction of TS transcript at 12h and a peak 30-fold
induction of TP transcript at 24h.
Finally, in order to confirm that our findings were shared by
other HDAC-Is, we tested the effects of several inhibitors with
different HDACs specificity on both TS and TP expression in LoVo
and SW620 cells. As shown in Figure 1D, we demonstrated the
induction of TP expression by other pan-HDAC-Is such as LBH589
or TSA and by class I HDAC-Is such as VPA and MS275.
Conversely, tubacin, a specific inhibitor of HDAC-6, does not
affect TP expression and slightly reduces TS expression.
Interestingly, in PBLs from healthy donors treated ex vivo with
vorinostat, we did not observe TP induction, but rather down-
regulation of both TP protein (Figure 2A) and mRNA (Figure 2C)
expression (2.5-fold peak reduction of TP transcript after 24h).
Moreover, when comparing PBLs with CRC LS174T cells, we
observed an undetectable basal level of TS protein unmodified by
vorinostat, whereas the TS transcript was slightly modulated by the
treatment (1.5-fold reduction after 24h) (Figure 2A and B). To
confirm that PBLs were effectively targeted by vorinostat, a
western blot analysis of acetylated histone H3 was performed,
demonstrating an increased histone-H3 acetylation at 24 and 48h
of treatment with vorinostat (Figure 2A).
These results suggest that vorinostat may increase sensitivity
to fluoropyrimidines such as 50-DFUR and capecitabine by
specifically modulating both TS and TP expression in cancer cells,
but not in normal controls.
In vitro synergistic antitumour effects of vorinostat in
combination with 50-DFUR
We next investigated the antitumour effect of vorinostat in
combination with the capecitabine metabolite 50-DFUR. We
demonstrated that combined treatment with equipotent doses of
vorinostat and 50-DFUR for 96h resulted in synergistic anti-
proliferative effects in LoVo, LS174T and SW620 cells as shown by
CIs values that were always lower than 0.8, calculated at 50% (CI50)
or 75% (CI75) of cell lethality (Table 2). Moreover, in all cell lines,
we measured a dose reduction in the IC50 values (DRI50) from
1.4- to 4.4-fold for both vorinostat and 50-DFUR in combination
compared with the concentrations of the two drugs alone.
Table 1 Sensitivity of colorectal cancer cell lines to vorinostat and fluoropyrimidines (5-FU, 5-FU/FA, 50-DFUR)
Cell lines
p53
status
KRAS
status
IC50 (±s.d.)
vorinostat
a
IC50 (±s.d.)
5-FU
a
IC50 (±s.d.)
5-FU/FA
a
IC50 (±s.d.)
50-DFUR
a
HT29 Mut Wt 1mM (±0.3) 1.4mM (±0.1) 0.7mM (±0.01) 8mM (±0.3)
HT29-FU Mut Wt 1.7mM (±0.4) 16mM (±0.2) 15mM (±0.15) 41000mM
LoVo Wt Mut (G13D) 0.7mM (±0.01) 2mM (±0.02) 1.8mM (±0.01) 16mM (±0.02)
SW620 Mut Mut (G12V) 0.45mM (±0.015) 0.45mM (±0.15) 2mM (±0.03) 78.5mM (±0.3)
LS174T Wt Mut (G12D) 0.98mM (±0.88) 13mM (±0.4) 8mM (±0.2) 4200mM
Abbrevaitons: 5-FU¼5-fluorouracil; 5-FU/FA¼fluorouracil modulated by folinic acid; 50-DFUR¼50-deoxy-5-fluorouridine; IC¼inhibitory concentration; Mut¼mutation;
Wt¼wild type.
aIC50 values were computed at 96h of treatment (mean±s.d. from at least three separate experiments performed in quadruplicates). The IC50 values of cells
resistant to fluoropyrimidines are highlighted in grey.
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Figure 1 Effect of vorinostat and of other HDAC-Is on TS and TP expression in CRC cells. (A) Basal protein expression of TS and TP were analysed by
western blotting in the CRC cell lines. GAPDH was used as protein loading control. (B) TS and TP proteins expression were determined by western blotting on
the indicated CRC cells untreated or treated with vorinostat at concentration corresponding to IC50
72h (1mM LoVo and LS174T cells and 2mM for SW620 cells) and
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their combination to induce apoptosis. In both LoVo and SW620
cells, using low doses (IC30
96h) of vorinostat (0.35 and 0.25mM,
respectively) and of 50-DFUR (7mM and 12mM, respectively), we
observed a significant increase in apoptosis induced by the
combination therapy compared with single agent treatments after
72h exposure (Figure 3A and B).
In the same conditions, in both LoVo and SW620
cells, vorinostat and 50-DFUR induced the expression of the
proapoptotic protein BAX or the cleavage of PARP. These effects
were even slightly increased or confirmed by combination
treatment (Figure 3C and D). Notably, the low doses of vorinostat
employed in the latter experiments were able to significantly
modulate TP expression (see Figure 1), suggesting that the
enhanced lethality of the combination treatment could be
attributed, at least in part, to this mechanism.
Knockdown of TP reduces the apoptotic effect of
vorinostat in combination with 50-DFUR
To determine if the vorinostat-induced expression of TP is
mechanistically correlated with the observed synergism we next
evaluated whether TP knockdown by a specific siRNA would affect
vorinostat/50-DFUR-mediated apoptosis.
As reported in Figure 4, SW620 cells transfected with siTP
construct showed a clear reduction of TP mRNA levels compared
with control siRNA transfected cells after 48 and 72h from
transfection (Figure 4A). Moreover, in those cells in which TP had
been knocked down the capacity of vorinostat to increase its
expression is dramatically reduced compared with control cells
(Figure 4B). Notably, in TP knocked down cells we did not observe
the increased induction of GADD45, a growth-arrest and
DNA-damage-inducible gene, observed in control siRNA-trans-
fected cells upon vorinostat/50-DFUR combination treatment
compared with single agent treatments (Figure 4C). Similarly both
PARP and caspase 3 cleavage induced by vorinostat/50-DFUR
combination treatment were significantly reduced in TP knocked
down cells (Figure 4D). Altogether these findings confirmed that at
least in part, the upregulation of TP expression induced by
vorinostat is critical for the synergistic antiproliferative and
apoptotic cell death induced by vorinostat/50-DFUR combination.
In vivo synergistic antitumour effect of vorinostat in
combination with capecitabine
To determine in vivo the presence of the synergistic antitumour
effects that were demonstrated in vitro, we evaluated vorinostat in
combination with capecitabine in a SW620 cell xenograft
experimental model in athymic nude mice by measuring tumour
volume (Figure 5A), TGD (Figure 5B), CIs (Figure 5C) and survival
(Figure 5D). A total of 36 xenografted mice were randomly
assigned to receive sub-therapeutic doses of vorinostat
(100mgkg
 1 p.o.), capecitabine (359mgkg
 1 p.o.), both drugs in
combination, or their vehicles as a control. Treatments were
administered 5 days/week for two weeks.
At day 27, which represents the median survival duration of
mice in the control group, the combination treatment induced a
significant inhibition (36±7%, Po0.005) of tumour growth
compared with single agent treatments (Figure 5A). The resulting
TGD reached a peak of 460%, indicating that the rate of tumour
growth in the control, at that point, was almost 2.4-fold higher
than in the combination treatment setting (Figure 5B). Single-
agent treatment of the indicated doses resulted in a slight growth
inhibition with no significant effects observed on TGD.
Furthermore, synergistic effects between vorinostat and capeci-
tabine were also confirmed by the evaluation of CIs reported vs
LCK (see Materials and Methods; Figure 5C). As a consequence,
substantial increases in survival were observed only in the group
treated with vorinostat plus capecitabine, as four out of nine mice
were still alive 30 days post-implantation (Po0.05).
Combinatory treatment of vorinostat plus capecitabine was well
tolerated, as shown by the maintenance of body weight (inset in
Figure 5A) and the absence of other signs of acute or delayed
toxicity.
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sVorinostat/capecitabine treatment decreased proliferation
markers, induced apoptosis and modulated TS and TP
expression in tumour xenografts
Analysis of mitotic and necrotic cells on H&E stained slides from
SW620 xenograft tumours demonstrated that combination treat-
ments induced a significant reduction of mitotic cells and a
contextual increase in the percentage of necrotic cells compared
with the untreated group or single-agent treatment group. More-
over, a significant increase of apoptosis as demonstrated by
TUNEL assay was observed in the vorinostat plus capecitabine
group compared with the untreated group or single-agent
treatment group (Figure 6A and 6B). Notably, as shown by IHC
analysis of xenograft tumours, the downregulation of TS and the
upregulation TP were also confirmed in vivo in the vorinostat and
the vorinostat plus capecitabine groups. Interestingly, TP protein
expression was also increased by capecitabine alone compared
with untreated controls. Finally, analysis of histone-H3 acetylation
demonstrated a significant increase in both the vorinostat and
vorinostat plus capecitabine groups compared with controls, as
expected, but we also observed an evident increase in the
capecitabine group.
Taken together these data confirmed our in vitro findings that
modulation of both TS and TP by vorinostat may be a potential
mechanism for the synergistic antitumour interaction observed
between vorinostat and capecitabine.
DISCUSSION
The results of the present study suggest a benefit from combining
vorinostat with capecitabine in CRC, indicating that the modula-
tion of TS and TP expression by vorinostat may explain the
synergistic interaction between these two drugs observed both
in vitro and in vivo. We demonstrated that coadministration of
these agents might represent a worthy strategy for more effectively
targeting de novo synthesis of dTMP and subsequent DNA
synthesis by fluoropyrimidines. Indeed, we showed that the
antiproliferative effect induced by vorinostat in CRC cells and in
xenograft tumours was paralleled by downregulation of TS protein,
the crucial enzyme for thymidilate synthesis and the target of
5-FU, and by upregulation of TP protein, a critical enzyme in the
final step of the metabolic transformation of capecitabine to
5-FU. Thymidine phosphorylase, by reversibly converting 5-FU
Table 2 Combination index (CI) and dose reduction index (DRI) values for vorinostat and 50-deoxy-5-fluorouridine (50-DFUR) combination treatment
DRI at IC50 ±s.d.
Cell lines CI50 ±s.d. vorinostat + 50-DFUR
a CI75 ±s.d vorinostat + 50-DFUR
a Vorinostat 50-DFUR
b
LoVo 0.78±0.13 0.76±0.1 2.3±1 4.4±2
LS174T 0.69±0.09 0.6±0.2 1.4±0.7 2±0.5
SW620 0.76±0.1 0.57±0.23 3.1±0.8 2.3±0.2
aCI values (mean±s.d. from at least three separate experiments performed in quadruplicates) computed at 50 and 75% of cell kill (CI50 and CI75, respectively) according by
CalcuSyn software after 96h of treatment. Combinations were considered strongly synergistic when CIs were below 0.9.
bDRI values (mean±s.d. from at least three separate
experiments performed in quadruplicates) represents the order of magnitude (fold) of dose reduction obtained for IC50 (DRI50) in combination setting compared with each drug
alone.
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sto 50-FUDR, which can be subsequently converted to 5FdUMP,
may also favour the formation of the stable inactive ternary
complex between this latter 5-FU-metabolite, the TS enzyme and
the methyl donor CH2THF (Figure 6C). Consequently, we
demonstrated that simultaneous exposure of vorinostat and the
capecitabine metabolite 50-DFUR in vitro resulted in synergistic
antiproliferative and proapoptotic effects in all CRC cell lines
examined, independent of p53 status and including cells strongly
resistant to 50-DFUR.
The synergistic effect demonstrated in vitro was also confirmed
in vivo in a human CRC xenograft model, in which a marked
inhibition of tumour growth, increased apoptosis and increased
survival were observed in vorinostat plus capecitabine combina-
tion compared with single agent treatments.
The association of treatment with pharmacodynamic readout of
efficacy represents a major challenge for novel targeted drugs.
Notably, our data demonstrated that the antitumour activity we
observed in vivo correlated with the induction of histone
acetylation, a marker of HDAC-Is activity, as well as with a
reduction in the markers of proliferation and induction of
apoptosis on tumour xenografts. Moreover, the modulation of
both TS and TP expression by vorinostat observed in vitro was
clearly confirmed in vivo, providing additional insights into the
mechanism of the synergistic interaction between vorinostat and
capecitabine. The observation that vorinostat downregulates TS
protein expression both in vitro and in vivo as a consequence of
vorinostat-induced attenuation of TS mRNA transcript confirmed
previous findings from our group and from others (Glaser et al,
2003; Lee et al, 2006; Tumber et al, 2007; Di Gennaro et al, 2009;
Fazzone et al, 2009). Thymidylate synthase protein was not
detectable by western blot analysis in nontumoural PBLs, and
vorinostat induced a late and less pronounced inhibition of TS
transcription in these cells compared with CRC cells. On the other
hand, to our knowledge, this is the first study to show that
vorinostat modulates the expression of TP both in vitro and
in vivo. Significantly, this effect was also shared by other pan-HDAC-Is
such as LBH589 or TSA and by class I HDAC-Is such as VPA and
MS275, but not by the specific inhibitor of HDAC-6 tubacin, indicating
that class I HDAC targeting is crucial for TP induction.
This is also the first study to demonstrate synergistic antitumour
effects between vorinostat and capecitabine in vivo in a preclinical
model. A recent paper by Guarcello et al (2008) showed that TP
expression can be suppressed in human cancer cells by promoter
methylation. This paper showed that treatment with methylation-
inhibitor 5-aza-20-deoxycytidine alone or in combination with
HDAC-I TSA resulted in increase TP mRNA and protein levels. We
showed that the upregulation of TP in CRC cells and in human
cancer cells of different tissues of origin (unpublished observation)
was independent of the basal level of TP. Notably, sublethal doses
of vorinostat, far below the maximum serum concentrations
reached with single agent therapy or in combination treatment in
cancer patients, were able to significantly modulate TP expression
within 24h, suggesting that the enhanced lethality of the
combination treatment could be primarily, if not exclusively,
attributed to this mechanism. In this regard, we also showed that
TP knockdown by a specific siRNA significantly impairs the
synergistic apoptotic cell death induced by vorinostat/50-DFUR
combination.
Intrinsic or acquired resistance to fluoropyrimidines is often
associated with TS overexpression, and it has also correlated with
low or deficient intratumoural TP activity (Salonga et al, 2000;
de Bruin et al, 2003). For this reason, our findings are clinically
relevant. Indeed, in this study, the induction of TP by vorinostat
and the synergistic interaction of vorinostat with 50-DFUR or
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scapectabine is also evident in two cell lines such as LS174T or SW620,
both of which express undetectable levels of TP protein and very low
levels of TP mRNA, as well as both being strongly resistant to
50-DFUR. Notably, in nontumoural PBLs treated ex vivo by
vorinostat, we observed a reduction of both TP protein and mRNA
expression. Consequently, we can assume that as demonstrated for
other genes, TP can be specifically modulated by HDAC-Is in tumour
cells in which it is deregulated either by promoter methylation or
other mechanisms, whereas normal cells are not affected. This latter
observation suggests that the increased antitumour effect observed in
tumour cells both in vitro and in vivo by combining vorinostat with
fluoropyrimidines should not translate into an increased toxicity in
normal cells. Indeed, no additional toxic effect was observed in vivo
in the combination treatment setting compared with single-drug
treatment. We are currently evaluating in-depth the mechanism as
well as the functional significance of the selective induction of TP in
tumour cells.
We are aware that TP showed a strong sequence homology to
the pro-angiogenic platelet derived endothelial cell growth factor
(PD-ECGF), such that the two enzymes are considered identical
(Ishikawa et al, 1989; Usuki et al, 1992; Moghaddam et al, 1995).
It has been shown that PD-ECGF/TP may contribute to angio-
genesis, tumour progression and metastasis via mechanisms that
remain to be defined (reviewed in Liekens et al, 2007; Koopman
et al, 2009). We have not investigated the effect of vorinostat on
signal transduction pathways leading to angiogenesis and/or meta-
stasis in our preclinical models; however, several reports have
clearly shown that HDAC-Is, including vorinostat, block tumour
invasion and metastasis as well as tumour-induced angiogenesis
(Kim et al, 2004; Qian et al, 2006; Shankar et al, 2009).
Capecitabine was designed to take advantage of the increased
levels of TP observed in tumours as opposed to normal tissues,
potentially allowing for selective toxicity in tumours (Bollag and
Hartmann, 1980; Walko and Lindley, 2005), and is a valuable
substitute for a bolus or infusion of 5-FU either as monotherapy or
in combination with other cytotoxic drugs in the treatment of
cancer types for which it is currently approved, such as breast and
CRCs. However, strategies for the potentiation of anticancer
activity of capecitabine are required to improve the therapeutic
index of this drug, and several current clinical efforts are focused
on the evaluation of TP-inducible therapy in combination with
capecitabine for cancer treatment (Liekens et al, 2007). Although
there is no direct demonstration of the role of TP, the clinical
investigation of TP-inducible chemotherapeutics, such as taxanes,
cisplatin or cyclophosphamide, in combination with capecitabine
showed increased response rate, time to progression and survival
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Figure 5 Antitumour activity of vorinostat and capecitabine on established colorectal cancer xenografts. SW620 cells (5 10
6) were subcutaneously
injected into athymic mice as described in the Materials and Methods. When established tumours were palpable, mice were treated with vorinostat
(100mgkg
 1 p.o.), capecitabine (359mgkg
 1 p.o.) or both drugs 5 days/week for two weeks. (A) Mean±s.d. tumour volume measured at pre-specified
time points (n¼9). *Pp0.001; and **Pp0.01. Inset, body weight measured three times per week. (B) Tumour growth delay (TGD), determined as
%TGD¼((T – C)/C) 100, where T and C are the mean times expressed in days for the treated or control groups, respectively, to reach a defined tumour
volume (see Materials and Methods). (C) In vivo vorinostat plus capecitabine combination studies evaluated by CalcuSyn. For the calculation of CI, the values
of log cell kill (LCK) for a fixed tumour volume were considered (see Materials and Methods). (D) Effect of vorinostat and/or capecitabine on the survival of
SW620 xenograft mice. Survival was analysed by Kaplan–Meier survival curves (P¼0.03 combination vs control). Mice were killed by cervical dislocation
when evidence of advanced bulky disease was present (cutoff, mean tumour volume¼2000mm
3), and the day of killing was considered the day of death for
survival evaluation.
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sin breast cancer patients in phase III studies. Promising results
were also seen in gastric and NSCLC in phase II studies (Kindwall-
Keller et al, 2005; Walko and Lindley, 2005; Ajani, 2006; Gelmon
et al, 2006).
Recently, two phase I pharmacokinetic and pharmacodynamic
studies have defined the maximum tolerated dose of vorinostat in
combination with FOLFOX (FOLFOX, fixed dose of 5-Fluorouracil,
leucovorin and oxaliplatin) or 5-FU/LV chemotherapy regimens
(Fakih et al, 2009, 2010) in CRC. However, no consistent effect of
vorinostat on TS expression in patient tumour samples was
demonstrated in both studies. Interestingly, clinical activity was
noted also in patients with 5-FU-refractory CRC (Fakih et al, 2010),
which agrees with our previous data demonstrating that vorinostat
sensitises 5-FU-resistant CRC cells to 5-FU. In conclusion,
although other enzymes such as dihydropyrimidine dehydro-
genase, which regulate the rate limiting step in the catabolism of
5-FU as well as the disregulation in tumour cells of critical path-
ways regulating survival, growth arrest or apoptosis, could be
related to the antitumour efficacy of fluoropyrimidines (Ishikawa
et al, 1999; Yen and McLeod, 2007) our results indicate that
vorinostat has the unique capability to modulate not only TS but
also TP expression in tumour cells (Figure 6C) and, consequently,
can synergise with capecitabine. In addition, both vorinostat and
capecitabine are drugs that can be administered orally with
consequent increased compliance for the patients. In conclusion,
our study showed that the combination of vorinostat and
capecitabine is a feasible and promising chemotherapeutic strategy
for colon cancer treatment and should be clinically explored.
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Figure 6 Effect of vorinostat/capecitabine treatment on proliferation, apoptosis, acetylation of histone H3, and expression of TS and TP in SW620
xenograft tumours. (A) Paraffin-embedded tissue was generated from each tumour for hematoxylin and eosin stain (H&E), TUNEL assay and
immunohistochemistry analysis for the indicated markers as described in the Materials and Methods. Images were captured with a 20  or 40  objective
on a light microscope. (B) Necrotic area was evaluated as the percentage of necrosis inner to tumoural nodule. Mitosis was evaluated as number of mitotic
figures in 10 high-magnification fields (Inset in A). Tumour sections stained for TUNEL, TS, TP or acetil-H3 were scored semiquantitatively for the percentage
of positive cells. The group means were calculated for n¼5 to seven tumours per group. All of the data are presented as the average±s.d. *Pp0.001; and
**Pp0.05, statistical significance compared with control. (C) Schematic depicting the mechanism of antitumour activity of capecitabine and the effects of
vorinostat. 5-FUTP¼5-fluorouridine triphosphate; 5FdUTP¼5-fluorodeoxyuridine triphosphate; 5FdUMP¼5-fluorodeoxyuridine monophosphate;
CE¼carboxylesterase; CyD¼cytidine deaminase; FdUrd¼20-deoxy-5-fluorouridine; FdUMP¼5-fluorodeoxyuridine monophosphate; OPRT¼orotate
phosphoribosyltransferase; TK¼thymidine kinase; TP¼thymidine phosphorylase; TS¼thymidylate synthase.
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